KYVERNA THERAPEUTICS INC (KYTX) Stock Price, Quote, News and Overview
NASDAQ:KYTX - Nasdaq - US5019761049 - Common Stock - Currency: USD
KYTX Quote, Performance and Key Statistics
NASDAQ:KYTX (5/27/2025, 1:40:22 PM)
2.775
+0.5 (+22.25%)
The current stock price of KYTX is 2.775 USD. In the past month the price increased by 8.1%. In the past year, price decreased by -82.54%.
KYTX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.03 | 327.00B | ||
| AMGN | AMGEN INC | 13.38 | 149.34B | ||
| GILD | GILEAD SCIENCES INC | 14.02 | 134.95B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 114.07B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.64 | 65.26B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 38.07B | ||
| ARGX | ARGENX SE - ADR | 99.29 | 35.59B | ||
| ONC | BEIGENE LTD-ADR | 6.06 | 25.63B | ||
| BNTX | BIONTECH SE-ADR | N/A | 23.69B | ||
| NTRA | NATERA INC | N/A | 21.50B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 19.34B | ||
| BIIB | BIOGEN INC | 8.15 | 18.88B |
Related stock screener links
About KYTX
Company Profile
Kyverna Therapeutics, Inc. is a cell therapy clinical-stage biotechnology company. The company is headquartered in Emeryville, California and currently employs 112 full-time employees. The company went IPO on 2024-02-08. The Company’s lead chimeric antigen receptor (CAR) T-cell therapy candidate, KYV-101, is advancing through clinical development with Phase II trials for stiff person syndrome and myasthenia gravis, and two ongoing multi-center Phase I/II trials for patients with lupus nephritis. KYV-101 is an autologous, fully human CD19 CAR T-cell product candidate incorporating highly potent CD28 co-stimulation. The firm is also harnessing investigator-initiated trials and other KYSA studies, including in multiple sclerosis and systemic sclerosis, to inform the next priority indications for the Company to advance into late-stage development. Its pipeline includes next generation CAR T-cell therapies in both autologous and allogeneic formats with properties intended to be well suited for use in B cell-driven autoimmune diseases.
Company Info
KYVERNA THERAPEUTICS INC
5980 Horton Street, Suite 550
Emeryville CALIFORNIA US
Employees: 112
Phone: 15106268331
KYVERNA THERAPEUTICS INC / KYTX FAQ
What is the stock price of KYVERNA THERAPEUTICS INC today?
The current stock price of KYTX is 2.775 USD. The price increased by 22.25% in the last trading session.
What is the ticker symbol for KYVERNA THERAPEUTICS INC stock?
The exchange symbol of KYVERNA THERAPEUTICS INC is KYTX and it is listed on the Nasdaq exchange.
On which exchange is KYTX stock listed?
KYTX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for KYVERNA THERAPEUTICS INC stock?
12 analysts have analysed KYTX and the average price target is 17.34 USD. This implies a price increase of 524.86% is expected in the next year compared to the current price of 2.775. Check the KYVERNA THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is KYVERNA THERAPEUTICS INC worth?
KYVERNA THERAPEUTICS INC (KYTX) has a market capitalization of 119.94M USD. This makes KYTX a Micro Cap stock.
How many employees does KYVERNA THERAPEUTICS INC have?
KYVERNA THERAPEUTICS INC (KYTX) currently has 112 employees.
What are the support and resistance levels for KYVERNA THERAPEUTICS INC (KYTX) stock?
KYVERNA THERAPEUTICS INC (KYTX) has a support level at 2.11 and a resistance level at 2.33. Check the full technical report for a detailed analysis of KYTX support and resistance levels.
Should I buy KYVERNA THERAPEUTICS INC (KYTX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of KYTX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of KYTX, evaluating the profitability, health, valuation and growth aspects
- KYVERNA THERAPEUTICS INC (KYTX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- KYVERNA THERAPEUTICS INC (KYTX) Sales and EPS estimates to see what analysts future expectations are.
- KYVERNA THERAPEUTICS INC (KYTX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- KYVERNA THERAPEUTICS INC (KYTX) Insider and Institutional Ownership to learn about the owners and their transactions.
- KYVERNA THERAPEUTICS INC (KYTX) Stock Chart to make your own analysis
- KYVERNA THERAPEUTICS INC (KYTX) Latest news and press-releases to stay up to date.
Does KYVERNA THERAPEUTICS INC (KYTX) stock pay dividends?
KYTX does not pay a dividend.
When does KYVERNA THERAPEUTICS INC (KYTX) report earnings?
KYVERNA THERAPEUTICS INC (KYTX) will report earnings on 2025-08-11.
What is the Price/Earnings (PE) ratio of KYVERNA THERAPEUTICS INC (KYTX)?
KYVERNA THERAPEUTICS INC (KYTX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.38).
What is the Short Interest ratio of KYVERNA THERAPEUTICS INC (KYTX) stock?
The outstanding short interest for KYVERNA THERAPEUTICS INC (KYTX) is 5.06% of its float. Check the ownership tab for more information on the KYTX short interest.
KYTX Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to KYTX. When comparing the yearly performance of all stocks, KYTX is a bad performer in the overall market: 94.32% of all stocks are doing better.
KYTX Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to KYTX. KYTX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
KYTX Financial Highlights
Over the last trailing twelve months KYTX reported a non-GAAP Earnings per Share(EPS) of -3.38. The EPS decreased by -97.2% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -55.79% | ||
| ROE | -64.92% | ||
| Debt/Equity | 0 |
KYTX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 82% to KYTX. The Buy consensus is the average rating of analysts ratings from 12 analysts.